The expression signature of androgen receptor splice variants and their distinctive transcriptional activities in castration-resistant prostate cancer

Androgen-Responsive Genes in Prostate Cancer: Regulation, Function and Clinical Applications

Volumn 9781461461821, Issue , 2013, Pages 201-213

  Plymate, Stephen R ^a   Luo, Jun ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen receptor; Androgen receptor splice variant; AR splice variant transcriptome; AR V7; ARV567ES; Castration resistant prostate cancer; Cell cycle

Indexed keywords

EID: 84907076794     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-6182-1_13     Document Type: Chapter

References (36)

1. Huggins C, Hodges CV (2002) Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 167:948-951, discussion 52
2. Eisenberger MA, Blumenstein BA, Crawford ED et al (1998) Bilateral orchiectomy with or withoutflutamide for metastatic prostate cancer. N Engl J Med 339:1036-1042
3. Chen Y, Sawyers CL, Scher HI (2008) Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 8:440-448
4. Attard G, Cooper CS, de Bono JS (2009) Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 16:458-462
5. Antonarakis ES, Eisenberger MA (2011) Expanding treatment options for metastatic prostate cancer. N Engl J Med 364:2055-2058
6. de Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005
7. Scher HI, Beer TM, Higano CS et al (2010) Antitumour activity of MDV3100 in castrationresistant prostate cancer: a phase 1-2 study. Lancet 375:1437-1446
8. Efstathiou E, Titus M, Tsavachidou D et al (2012) Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol 30:637-643
9. Dehm SM, Tindall DJ (2011) Alternatively spliced androgen receptor variants. Endocr Relat Cancer 18:R183-R196
10. Hu R, Denmeade SR, Luo J (2010) Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer. Expert Rev Endocrinol Metab 5:753-764
11. Andersen RJ, Mawji NR, Wang J et al (2010) Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 17:535-546
12. Sadar MD (2011) Small molecule inhibitors targeting the "Achilles' Heel" of androgen receptor activity. Cancer Res 71(4):1208-1213
13. Yamashita S, Lai KP, Chuang KL et al (2012) ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. Neoplasia 14:74-83
14. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ (2008) Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68:5469-5477
15. Hu R, Dunn TA, Wei S et al (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69:16-22
16. Guo Z, Yang X, Sun F et al (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69:2305-2313
17. Watson PA, Chen YF, Balbas MD et al (2010) Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 107:16759-16765
18. Sun S, Sprenger CC, Vessella RL et al (2010) Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120:2715-2730
19. Hu R, Isaacs WB, Luo J (2011) A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate 71(15):1656-1667
20. Yang X, Guo Z, Sun F et al (2011) Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells. J Biol Chem 286:36152-36160
21. Zhou ZX, Sar M, Simental JA, Lane MV, Wilson EM (1994) A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH2-terminal and carboxyl-terminal sequences. J Biol Chem 269:13115-13123
22. Chan SC, Li Y, Dehm SM (2012) Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. J Biol Chem 287:19736-19749
23. Jenster G, van der Korput HA, van Vroonhoven C, van der Kwast TH, Trapman J, Brinkmann AO (1991) Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol 5:1396-1404
24. Hu R, Lu C, Mostaghel EA et al (2012) Distinct transcriptional programs mediatd by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 72(14):3457-3462
25. Pan Q, Saltzman AL, Kim YK et al (2006) Quantitative microarray profiling provides evidence against widespread coupling of alternative splicing with nonsense-mediated mRNA decay to control gene expression. Genes Dev 20:153-158
26. Zhang X, Morrissey C, Sun S et al (2011) Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One 6:e27970
27. Hornberg E, Ylitalo EB, Crnalic S et al (2011) Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One 6:e19059
28. Liu W, Laitinen S, Khan S et al (2009) Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 15:559-565
29. Li Y, Alsagabi M, Fan D, Bova GS, Tewfik AH, Dehm SM (2011) Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res 71:2108-2117
30. Li Y, Hwang TH, Oseth L, et al (2012) AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene 31(45):4759-4767
31. Mostaghel EA, Marck BT, Plymate SR et al (2011) Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 17:5913-5925
32. Cai C, He HH, Chen S et al (2011) Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase Cancer Cell 20:457-471
33. Tran C, Ouk S, Clegg NJ et al (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324:787-790
34. Cai C, Chen S, Ng P et al (2011) Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res 71:6503-6513
35. Subramanian A, Tamayo P, Mootha VK et al (2005) Gene set enrichment analysis: a knowledge- based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102:15545-15550
36. Bolton EC, So AY, Chaivorapol C, Haqq CM, Li H, Yamamoto KR (2007) Cell- and genespeci fic regulation of primary target genes by the androgen receptor. Genes Dev 21:2005-2017